Investor Overview Announcements Date Title 2024/05/02 Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for Phase II human clinical trial 2023/04/25 Announcement of the Company’s board meeting date to approve 2024Q1 consolidated financial report Read More Annual Report 2022 Annual Report (PDF)General Shareholders’Meeting Notice (PDF)General Shareholders’Meeting Minutes (PDF)General Shareholders’Meeting Handbook (PDF) See More Financial Report 2023Q3 Consolidated See More Stock Quote See More Event Calendar See More Monthly Revenues See More Corporate GovernanceRead More StakeholderRead More Company Profile Read More